Duration and active metabolites separate two sulfonylureas, and MN553's Unit 4 comparison chooses glipizide over glyburide for a composite older man with reduced clearance. Searches like "mn 553 unit 4 assignment example", "mn553 unit 4 sample" and "mn553 unit 4 example" land here.
Glipizide Versus Glyburide for a 77-Year-Old With a Creatinine Clearance of 38 mL/min and Irregular Meals: A Drug Class Comparison
[Student Name]
Purdue University Global
MN553: Advanced Pharmacology
Unit 4 Assignment
[Instructor Name]
[Date]
Composite patient written as a model document. No real patient is described, and nothing here is a prescribing instruction.
The Case
A composite 77-year-old retired machinist has type 2 diabetes managed with metformin 500 mg twice daily, reduced last year when his kidney function declined, and his most recent hemoglobin A1C is 8.4 percent. He weighs 68 kg, and his serum creatinine is 1.57 mg/dL. Using the Cockcroft-Gault equation, (140 minus 77) x 68 / (72 x 1.57), his estimated creatinine clearance is 38 mL/min (Cockcroft & Gault, 1976). His wife died four months ago. Since then he eats when he remembers to, sometimes skipping lunch entirely and sometimes eating a large late supper. He lives alone, drives, and has Medicare Part D coverage. He has declined injectable therapy. For the purpose of this comparison, a sulfonylurea has already been chosen as the add-on agent, and the question is which one.
Comparison Table
Mechanism. Glipizide: closes ATP-sensitive potassium channels on pancreatic beta cells, depolarizing the cell and releasing insulin. Glyburide: identical.
Glucose dependence of insulin release. Both: none; insulin is released regardless of the current glucose level.
Onset. Glipizide: about 30 minutes for the immediate-release tablet. Glyburide: about 1 hour.
Duration of effect. Glipizide: about 12 to 24 hours. Glyburide: about 24 hours, often longer in older adults.
Metabolism. Glipizide: hepatic, to inactive metabolites. Glyburide: hepatic, to metabolites that retain glucose-lowering activity.
Elimination. Glipizide: inactive metabolites excreted mainly in urine. Glyburide: active metabolites cleared partly by the kidney, so they accumulate when clearance falls.
Hypoglycemia risk in older adults. Glipizide: present, lower within the class. Glyburide: highest within the class.
AGS Beers Criteria, 2023 update. Both: avoid as first- or second-line therapy unless there are substantial barriers to preferred agents; if a sulfonylurea is used, short-acting glipizide is preferred over long-acting glyburide (American Geriatrics Society Beers Criteria Update Expert Panel, 2023).
Cost. Both: generic, low-tier on most Part D formularies, typically a few dollars a month.
The Row Both Columns Share
Both drugs act at the same channel in the same way. By closing ATP-sensitive potassium channels on beta cells, they cause depolarization, calcium entry and insulin release, and they do so whether the blood glucose is high or low. That shared mechanism is also a shared danger. When a person on a sulfonylurea skips a meal, insulin is still released, and glucose can fall below a safe level with no food coming in to meet it. For this patient, whose meals have become unpredictable since his wife's death, the shared mechanism means that neither drug is free of risk. The question is which one limits that risk best given his other features.
Where the Columns Part
The decisive difference is metabolism. Glipizide is converted in the liver to inactive products, so its glucose-lowering effect ends when the parent drug is cleared, regardless of kidney function. Glyburide is converted to metabolites that still lower glucose, and these depend partly on the kidney for removal. With a creatinine clearance of 38 mL/min, those active metabolites would be cleared slowly and could accumulate, extending and deepening glyburide's effect beyond what its label duration suggests.
Duration compounds the problem. Glyburide already acts for about a day in healthy adults, and accumulation of active metabolites can extend that further in an older adult with reduced kidney function. For a man who might skip lunch and eat a late supper, a drug still acting strongly through the night and into the next morning creates long windows in which insulin is released without food. Glipizide's shorter action, with no active metabolites, narrows those windows. His unpredictable appetite and his reduced clearance point in the same direction.
An Unpredictable Appetite as a Case Fact
His eating pattern is treated here as a clinical finding, not as background. Since his wife's death he reports skipping lunch on three or four days a week and sometimes eating only toast in the evening. On other days he eats a large supper at 9 p.m. after forgetting to eat earlier. A sulfonylurea taken in the morning assumes that food will follow. For him it often will not, and the gap between dose and meal is exactly when glucose-independent insulin release is most dangerous. The pattern also has a second meaning. Loss of appetite and irregular eating four months after a bereavement can reflect grief or depression, which would affect his ability to manage any regimen. The comparison therefore records two actions outside the drug choice itself: screening for depression at this visit, and a discussion of when to take the tablet, with breakfast only on days he actually eats breakfast, and what to do if he does not. He drives, so hypoglycemia is also a road safety issue, and he would be taught to check his glucose before driving.
The Beers Entry, Read in Full
The 2023 AGS Beers Criteria do not ban sulfonylureas. The entry advises avoiding the class as first- or second-line therapy in older adults unless there are substantial barriers to the use of preferred agents, such as metformin, GLP-1 receptor agonists or SGLT2 inhibitors, and states that if a sulfonylurea is used, short-acting agents such as glipizide are preferred over long-acting ones such as glyburide (American Geriatrics Society Beers Criteria Update Expert Panel, 2023). This paper concedes that a different class might be the better add-on for him. An SGLT2 inhibitor would carry little risk of hypoglycemia, and current diabetes standards favor such agents in older adults with reduced kidney function when they are suitable (American Diabetes Association Professional Practice Committee, 2025). The case assumes a sulfonylurea because he has declined injections and because the question set for this unit is a within-class comparison. Within that assumption, the Beers entry supports glipizide explicitly.
What Would Show the Choice Was Right
The evidence of effect would be gathered at home and at follow-up. He would record fasting and pre-supper glucose readings from a home meter, with special attention to days when he skips a meal. A count of readings below 70 mg/dL, and any symptoms of shakiness, sweating or confusion, would be reviewed at a two-week check. An A1C at three months would be compared with an individualized target; for a 77-year-old living alone with a recent bereavement and irregular meals, a less stringent target, such as below 8.0 percent, would reduce hypoglycemia risk (American Diabetes Association Professional Practice Committee, 2025). Kidney function would be rechecked because his clearance is close to thresholds that affect metformin as well. If low readings occurred despite glipizide, the finding would argue for moving away from the sulfonylurea class rather than changing to another member of it.
References
American Diabetes Association Professional Practice Committee. (2025). Standards of care in diabetes 2025. Diabetes Care, 48(Suppl. 1), S1-S352. https://diabetesjournals.org/care
American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081. https://doi.org/10.1111/jgs.18372
Cockcroft, D. W., & Gault, M. H. (1976). Prediction of creatinine clearance from serum creatinine. Nephron, 16(1), 31-41. https://doi.org/10.1159/000180580
How this MN553 Unit 4 example is structured
What the two drugs share comes before how they differ, since both act identically at the channel. The shared mechanism row explains the shared danger: insulin release that does not depend on glucose can push a level too low when a meal is missed. Each divergent row is tied to one feature of the patient. Active metabolites matter because his kidneys clear them slowly; duration matters because his meals are irregular; the Beers listing is cited for its preference among sulfonylureas, not as a ban. One paragraph concedes that the 2023 criteria favor other classes before any sulfonylurea, and records why the case assumes one is already chosen. Evidence of effect closes the paper: fasting and pre-supper glucose logs, an A1C at three months against an individualized target, and a count of low readings.
Get an MN553 Unit 4 example written to your instructions
Two agents and one described patient are all the Unit 4 comparison needs from your MN553 section, along with whatever table format and grading sheet it specifies. Returned in 24-48h and free the first time, the sample builds its table from shared mechanism outward and ties each difference to a fact in the case. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
MN553 Unit 4 questions, answered
How many rows should a class comparison table have?
Enough to hold every difference that matters for the patient, and no more. Mechanism, metabolism, elimination, duration, key adverse effects, interactions and cost cover most prompts. Rows that are identical for both agents can be merged, and a row that never influences the recommendation is usually better cut than kept for completeness.
Is it acceptable to recommend neither agent?
Sometimes, where the prompt permits and the case supports it. Here the current Beers Criteria would favor a different class altogether for many older adults, and a paper may say so. If the prompt insists on choosing between the two supplied, the stronger answer makes the choice and records the reservation in a sentence rather than refusing the task.
Why does meal timing appear in a pharmacology paper?
Because the pharmacology makes it matter. A drug that releases insulin regardless of glucose keeps doing so when food does not arrive, so a patient's eating pattern changes the risk of the same agent. Case details like appetite, shift work or living alone are rarely decoration in these prompts; they are usually there to be connected to a mechanism.